Purpose

The main purpose of this study is to evaluate a new type of gamma camera (the Veriton system) that provides a significant gain in system sensitivity and improved image quality compared to a conventional gamma camera that can achieve equal or better image quality than a standard SPECT/CT system.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults age 18 years or older. - Currently scheduled to undergo a nuclear medicine exam.

Exclusion Criteria

  • Individuals under 18 years of age. - Unwilling/unable to sign an informed consent form. - Unable to lie on a Veriton imaging table for up to 40 minutes.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
each patient will have 2 scans - one on a conventional system and one on the newer technology
Primary Purpose
Diagnostic
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Evaluation of the Veriton SPECT/CT system
To determine if the Veriton system can achieve equal or better image quality than a standard SPECT/CT system.
  • Diagnostic Test: Veriton SPECT/CT
    The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.

Recruiting Locations

Mayo Clinic in Rochester
Rochester, Minnesota 55905

More Details

NCT ID
NCT04722185
Status
Recruiting
Sponsor
Mayo Clinic

Study Contact

Kera Delaney
507-293-5660
Delaney.Kera@mayo.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.